Biotech entity
Every one of those 3 sits in a single category, clinical-trial. Eli Lilly is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. Each story carries 2 original sources on average, compared with 3.4 for the broader beat in this window.
Last mentioned: Jun 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 33 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 3 sits in a single category, clinical-trial. Eli Lilly is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. Each story carries 2 original sources on average, compared with 3.4 for the broader beat in this window. Their average consequence score of 7.3 runs above the beat's 6.1 for that window. That works out to roughly 0.8 stories per week across a 25-day span. We currently track 3 Biotech stories that mention Retatrutide, published between February 24, 2026 and March 20, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 334 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Retatrutide. Shared-story counts are live from our verified record — not editorial picks.
RBC Capital has reaffirmed its bullish outlook on Eli Lilly’s Retatrutide, identifying the triple-agonist as a primary long-term growth driver despite mixed clinical trial data. Analysts suggest that the drug's unprecedented weight-loss efficacy will likely overshadow manageable safety concerns, securing Lilly's dominance in the metabolic health sector.
Eli Lilly's triple-agonist retatrutide achieved a 1.9% reduction in blood sugar levels in its first Phase 3 trial for type 2 diabetes. While the results are clinically significant, they appear to slightly trail the top-line efficacy of Lilly's own blockbuster Mounjaro, shifting the industry focus toward the drug's potential for superior weight loss.
Novo Nordisk's experimental triple-G agonist demonstrated nearly 20% weight loss in a 26-week Phase 2 trial, positioning it as a potent competitor to Eli Lilly’s retatrutide. While the efficacy data appears slightly superior to Lilly's mid-stage results, Novo remains on track to reach the market after its rival.
Retatrutide is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
